MyFiziq CompleteHealth app soon to be released
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Positive news continues to flow from MyFiziq Limited (ASX:MYQ) with management providing an update today on progress and designs of the new and soon to be released CompleteHealth application with Canadian based NuraLogix Corporation.
As a backdrop, MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track and assess their dimension using only a smartphone privately and accurately.
This technology has attracted other players in adjacent industries, resulting in the negotiation of agreements to work together to develop compelling new products.
These developments have seen the company’s shares increase four-fold since March.
MyFiziq signed a Memorandum of Understanding (MoU) with Canadian base Nuralogix Corporations in mid-June, and this was the key focus of today’s update.
Under the MoU, MyFiziq will be designing and developing the integrated offering, with a view to initially releasing it to only two organisations for testing and evaluation.
Demand from multiple industries
MyFiziq has had an influx of inquiries from telehealth, wellness, pharmacy chains, diabetes management organisations and insurers to the extent that the companies have agreed to make the application available to a greater number of these groups than previously anticipated.
The non-invasive combined solution delivers complete privacy to the consumer, which culminates in the individual being given assessments on multiple levels.
These include health indicators such as blood-pressure, heart rate, body shape ratios and a person’s propensity to develop cardiovascular conditions and type II diabetes.
Not including the current pandemic, this culmination of conditions form up to 70% of deaths globally each year,
Management said that it will allow an option for an individual to engage in an in-app COVID-19 symptoms analysis, which has been developed and tested by NuraLogix in collaboration with St. Michael’s Hospital, University of Toronto, and Zhongda Hospital in China to produce an AI-based model which is trained and tested on the symptom’s profiles of COVID-19 patients.
The model would predict the likelihood of someone having COVID-19 versus seasonal flu or cold.
Commenting on these developments, chief executive Vlado Bosanac said, “The team has done an exceptional job designing the new application, which will be called CompleteHealth.
‘’I am extremely pleased with the amount of interest this has generated, effectively validating our initial thoughts on the value we will bring to communities by combining these solutions.
‘’Importantly, we are identifying several chronic disease markers that have severe implications, should the user be exposed to COVID-19.
‘’The comorbidities such as obesity, type 2 diabetes, respiratory disease and cardiovascular disease that are being identified through the process are important information for the user to consider upon the evaluation being completed.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.